pd-l1 expression in early nsclc: interpreting the data so far | heather wakelee & nasser altorki
Published 2 years ago • 503 plays • Length 30:02Download video MP4
Download video MP3
Similar videos
-
9:24
impower010 supports adjuvant atezolizumab in early-stage nsclc | heather wakelee
-
3:50
pd-l1 expression in nsclc
-
2:01
dr. welsh on new understanding of regulating pd-l1 expression
-
59:37
drs. altorki & spicer discuss #nsclc #immunotherapy at #thoracicsummit2022 - https://bit.ly/3bxcsbv
-
18:58
pd-l1 testing by immunohistochemistry
-
17:57
dichloroacetate (dca) kills cancer & reverses warburg effect by inhibiting pdk
-
7:37
how to interpret a pd-l1 immunostain
-
1:16
dr. suzanne l. topalian on pd-l1 and emerging biomarkers for immunotherapy
-
1:10:47
watch drs. liu, aggarwal, higgins, and stiles discuss nsclc updates: https://bit.ly/3zamndg
-
3:29
pd-l1 status: what is the current role?
-
6:28
targeted therapy for alk-positive nsclc: a practical case study | biomarker-guided therapy in nsc...
-
2:22
dr. pennell on the evolution of targeting her2 in lung cancer
-
1:21
dr. o’donnell on pd-l1 testing in bladder cancer
-
1:00
dr. nadler discusses role of pd-l1 in squamous nsclc
-
2:07
dr. creelan discusses results of anti-pd-l1 antibody in combination with gefitinib in nsclc
-
2:53
comparison of three different pd-l1 diagnostic tests shows a high degree of concordance
-
1:44
pd-l1 testing in first-line treatment of nsclc
-
2:49
nsclc: the increasing need for pd-l1 testing
-
1:55
dr. hirsch on value of pd-l1 testing in patients with lung cancer
-
1:13
dr. herbst on targeting pd-1 and pd-l1 in lung cancer
-
6:21
the emergence of pd-l1 inhibitors